Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Overview
- Phase
- N/A
- Intervention
- 18F-DCFPyL
- Conditions
- Renal Cell Carcinoma
- Sponsor
- Johns Hopkins University
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Number of Participants With a Correlation Between Radiotracer Uptake on 18F-DCFPyL PET/CT and Conventional Imaging
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
In this study the investigators aim to evaluate diagnostic utility of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma (RCC).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinically diagnosed or histologically proven stage II-IV renal cell carcinoma
- •Completed staging evaluation with computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis ≤90 days prior to study enrollment
Exclusion Criteria
- •History of other malignancy diagnosed within the last 3 years (with the exception of low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma or basal cell carcinoma of the skin)
- •Administered a radioisotope within 5 physical half-lives prior to study enrollment
- •Pregnancy ((as determined in accordance with the policies of the positron emission tomography (PET) center))
- •Intention to enroll in a blinded therapeutic clinical trial following Positron emission tomography-computed tomography (PET/CT)
Arms & Interventions
18F-DCFPyL PET/CT
Intervention: 18F-DCFPyL
18F-DCFPyL PET/CT
Intervention: PET/CT
Outcomes
Primary Outcomes
Number of Participants With a Correlation Between Radiotracer Uptake on 18F-DCFPyL PET/CT and Conventional Imaging
Time Frame: 12 Months
This was assessed to Correlate Sites of Radiotracer Uptake on 18F-DCFPyL PET/CT With Conventional Imaging Findings.
Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC)
Time Frame: 12 Months
This was assessed to compare the sites of disease images of patients with RCC on conventional imaging with the images on the 18F-DCFPyL PET/CT to evaluate the sensitivity of DCFPyL PET/CT scans in detecting sites of disease compared to conventional imaging.